Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lushang Freda Pharmaceutical Co (SHSE:600223) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lushang Freda Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥3,059 Mil.
Lushang Freda Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥208 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co EV-to-EBIT Related Terms
Lushang Freda Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co EV-to-EBIT Competitor Comparison
For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lushang Freda Pharmaceutical Co EV-to-EBIT vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lushang Freda Pharmaceutical Co's EV-to-EBIT falls into.
Lushang Freda Pharmaceutical Co's current Enterprise Value is ¥3,741 Mil.
Lushang Freda Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥208 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co (SHSE:600223) has a EV-to-EBIT of 17.99 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lushang Freda Pharmaceutical Co and its competitors. This is 17% below median its historical median of 21.70. Over the past decade, Lushang Freda Pharmaceutical Co's EV-to-EBIT has ranged from 10.54 to 47.76. According to the industry distribution chart, Lushang Freda Pharmaceutical Co ranks #869 out of 1345 companies in the Real Estate industry, placing it in the top 64.6%.
Is Lushang Freda Pharmaceutical Co's EV-to-EBIT too high?
Lushang Freda Pharmaceutical Co's current EV-to-EBIT of 17.99 is 17% below median its 10-year median of 21.70. Over the past 10 years, this metric has ranged from a low of 10.54 to a high of 47.76. The Real Estate industry median EV-to-EBIT is 13.36. Lushang Freda Pharmaceutical Co's value of 17.99 is 34.7% above this industry median. Based on the distribution chart, Lushang Freda Pharmaceutical Co ranks #869 out of 1345 companies in the Real Estate industry, which is below the industry midpoint. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's EV-to-EBIT compare to competitors?
According to the Real Estate industry distribution chart, Lushang Freda Pharmaceutical Co ranks #869 out of 1345 companies for EV-to-EBIT. This places Lushang Freda Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 13.36. Lushang Freda Pharmaceutical Co's value of 17.99 is 34.7% above this benchmark. Historically, Lushang Freda Pharmaceutical Co's own EV-to-EBIT has ranged from 10.54 to 47.76 over the past decade. While the company's 10-year median is 21.70 vs. the industry median of 13.36, Lushang Freda Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Real Estate company?
The median EV-to-EBIT among Real Estate companies is 13.36, based on 1,345 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lushang Freda Pharmaceutical Co's current EV-to-EBIT of 17.99 is 34.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lushang Freda Pharmaceutical Co and its competitors. For the Real Estate industry, the median EV-to-EBIT is 13.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lushang Freda Pharmaceutical Co's current EV-to-EBIT is 17.99, which is 17% below median its own 10-year median of 21.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.03, compared to a current price of ¥5.71 — trading 18.8% below its estimated fair value. The current EV-to-EBIT is 17.99, which is 17% below median its 10-year median of 21.70 and 34.7% above the Real Estate industry median of 13.36. Lushang Freda Pharmaceutical Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current EV-to-EBIT is 17.99 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥5.71 is trading 18.8% below its estimated GF Value™ of ¥7.03.
GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600223:
EV-to-EBIT: 17.99 (17% below median its 10-year median of 21.70)
GF Value™: ¥7.03 vs. price of ¥5.71 (18.8% below fair value)
Industry Position: 34.7% above the Real Estate median (#869 of 1345)
No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
67GF Score
Get the complete analysis for SHSE:600223
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600223 has been successfully added to your 
